TickerFacts.

Apimeds Pharmaceuticals US, Inc. (APUS): Cash & Equivalents

Annual figures by period end, from SEC filings.

$1.64M
As of 2025-12-31
$278.4K
As of 2026-06-30
2023-12-31: $410.5K2024-12-31: $3.5K2025-12-31: $1.64M$1.64M
2023-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$1.64Mn/m2026-05-04, Balance as of period end
2024-12-31$3.5K-99.2%2026-05-04, Balance as of period end
2023-12-31$410.5Kn/a2025-04-15, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Apimeds Pharmaceuticals US, Inc. (APUS)2025-12-31$1.64Mn/m
Cypherpunk Technologies Inc. (CYPH)2025-12-31$14.04M-70.3%
Transcode Therapeutics, Inc. (RNAZ)2025-12-31$17.81M+206.5%
Gyre Therapeutics, Inc. (GYRE)2025-12-31$37.07M+213.8%
Climb Bio, Inc. (CLYM)2025-12-31$35.69M-59.1%
Aclaris Therapeutics, Inc. (ACRS)2025-12-31$19.96M-18.8%
Corbus Pharmaceuticals Holdings, Inc. (CRBP)2025-12-31$28.49M+65.7%
Eledon Pharmaceuticals, Inc. (ELDN)2025-12-31$22.81M+11.0%
Boundless Bio, Inc. (BOLD)2025-12-31$17.87M-32.8%

Compare APUS, CYPH, RNAZ, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗